and in the articles on epidemiology of sudden cardiac death in this compendium series.
The physiological mechanisms reported to cause SCD vary with the patient population and the criteria used to define SCD. 5, 6 In general, ventricular tachyarrhythmias, including ventricular fibrillation and pulseless ventricular tachycardia, are the most common electrophysiological mechanisms leading to SCD. 5, 7 Other physiological events that can result in SCD include pulseless electric activity, bradyarrhythmias, and asystole. 8, 9 This review will focus only on SCDs attributed to ventricular tachyarrhythmias.
Ventricular tachyarrhythmias, like all cardiac arrhythmias, result from 1 of 3 primary mechanisms: reentry, abnormal automaticity, or triggered activity. Reentry is the most common mechanism for ventricular tachyarrhythmias, involving the presence of an anatomic or functional disturbance of cardiac electric impulse propagation and of heterogeneous conduction. Abnormal automaticity results from the accelerated generation of an action potential by a region of ventricular cells. Triggered activity occurs when an action potential elicits subsequent depolarizations earlier (early afterdepolarization [EAD] ) or later (delayed afterdepolarization [DAD] ) in the repolarization phase.
All 3 mechanisms can result from abnormal functioning of myocardial ion channels and transporters, leading to disordered initiation or propagation of cardiac action potentials. Accumulating evidence suggests that altered cardiac ion channel/transporter function is closely linked to abnormal myocardial metabolic activity and imbalanced redox states in a wide range of cardiac pathology. This review presents the current evidence on the acute effects of abnormal myocardial metabolism and increased oxidative stress on myocardial ion channel/transporters that predispose to ventricular arrhythmias and SCD. It is important, however, to recognize that abnormal metabolism and oxidative stress in noncardiac myocytes tissues can also contribute to the development of ventricular arrhythmias. For example, altered metabolism and redox state have been implicated in vascular tissue leading to atherosclerosis, [10] [11] [12] [13] which underlies the main substrate for SCD and coronary heart disease. 2, 3 Another example is that abnormal metabolism and increased oxidative stress affect autonomic nervous system, thereby contributing to ventricular arrhythmias and SCD. [14] [15] [16] [17] Within the ventricle, chronic effects of such entities as diabetes mellitus and ischemia from atherosclerosis work through mechanisms involving metabolic and oxidative abnormalities to create the substrate of structural heart diseases that leads to SCD. Both the role of aberrant metabolism and oxidants in the chronic creation of such substrate will not be further considered.
Overview of Cardiac Ionic Channels and Membrane Excitability
Normal functioning of the mammalian heart depends on proper electric activity involving the initiation of the electric impulse from pacemaker cells, the propagation of the electric activity through specialized conduction system and myocardium, and the generation of action potentials in individual myocytes. 18, 19 A normal cardiac cycle begins with the action potential originating from the cells in sinoatrial node, conducts through the atria, atrioventricular node, His bundle, Purkinje fibers, and then spreads throughout the entire ventricular myocardium. 20 The proper propagation of cardiac electric impulse depends on low resistance pathways between cells via gap junctions, which are formed by docking of 2 connexin hemichannels on appositional sarcolemmal membranes. 21 Cardiac action potentials are generated through the coordinated activity of various types of ion channels and transporters ( Figure 1 ). Inward current conducting through the voltage-gated Na + channel rapidly depolarizes the cell (phase 0), which is followed by early repolarization (phase 1) attributed to the transient outward K + current (I to ). Depolarizing L-type Ca 2+ currents (I CaL ) and multiple repolarizing delayed rectifier K + currents (I K ) form the plateau phase (phase 2), which is followed by rapid repolarization (phase 3) with inactivated I CaL and increasing I K . The repolarization continues with the contribution of inwardly rectifying K + current, I K1, until return to the resting membrane potential (phase 4 action potential triggers the opening of ryanodine receptor 2 (RyR2) on the sarcoplasmic reticulum (SR), triggering the release of Ca 2+ from SR into the cytosol. Ca 2+ then binds to troponin-C of the troponin-tropomyosin complex, resulting in sarcomere longitudinal shortening.
During the diastolic phase, Ca 2+ is removed from the cytosol through sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA), which pumps cytosolic Ca 2+ into SR, as well as Na + /Ca 2+ exchanger (NCX), an antiporter membrane protein extruding 1 Ca 2+ ion from the myocyte in exchange for three Na + ions. Importantly, the maintenance of Na + and K + gradients across the plasma membrane is mediated by the Na + /K + ATPase, one of the more energy-consuming cellular processes in cardiac myocytess. The energy stored in the resultant electrochemical Na + gradient and K + gradient provides the driving force for many other transporter/exchangers. Conditions that impair the activity of the aforementioned ion channels/transporters can result in abnormal myocardial electric functioning, leading to ventricular arrhythmias and SCD.
Myocardial Metabolism and Energetics
Under physiological conditions, >90% of ATP produced in the cardiac myocytes is supplied by mitochondria via oxidative phosphorylation (OXPHOS), and the remainder comes from glycolysis and GTP derived from the tricarboxylic acid cycle. 22 As the predominant energy generator in the heart, mitochondria occupy ≈30% of the volume of cardiac myocytess. 23 The mitochondria have double-membrane structure (inner and outer membranes) that forms separate compartments, the intermembrane space, and mitochondrial matrix. Mitochondria metabolize predominantly fatty acids but can metabolize glucose to generate ATP via OXPHOS. Acetyl-CoA, the metabolic intermediate derived from sequential oxidation of glucose and fatty acid, is used to generate the reducing equivalents, nicotinamide adenine dinucleotide (NADH), and flavin adenine dinucleotide (FADH 2 ), in the tricarboxylic acid cycle. NADH and FADH 2 feed electrons to the electron-transport chain (ETC) residing on the mitochondrial inner membrane (Figure 2 ), where the electrons pass sequentially through complex I, II, III, and IV and finally interact with molecular O 2 to form H 2 O. Redox reactions occur at complex I, III, and IV, driving proton (H + ) from mitochondrial matrix into the intermembrane space. The resulting proton gradient and strongly negative mitochondrial membrane potential (∆Ψ m =−150 to −180 mV) 24 help to drive H + flow back to the matrix through mitochondrial ATP synthase (complex V), allowing the conversion of ADP to ATP (Figure 2) .
In healthy adult myocardium, 60% to 90% of acetyl-CoA comes from β-oxidation of fatty acids, whereas 10% to 40% comes from oxidation of pyruvate derived from glycolysis and lactate oxidation. 25, 26 Although the majority of cardiac ATP is consumed by the myofilaments, it is estimated that ≈25% of cardiac ATP hydrolysis is used to fuel sarcolemmal and SR ion channels and transporters. 27 The critical dependence of cardiac ion channels and transporters on energy supply from metabolized carbon fuels becomes evident under conditions such as myocardial ischemia, during which the mismatch between ATP supply and use can readily disrupt the cardiac rhythm through depleting energy supply to these channels and transporters.
28,29

Cardiac Oxidants and Oxidative Stress
In biological systems, partially reduced forms of oxygen (O 2 ) lead to the formation of oxidants or reactive oxygen species (ROS), which oxidize other molecules when these molecules accept electrons. The main ROS in cardiac myocytess exist in radical forms, such as superoxide (O 2
•− ) and hydroxyl radicals, or in nonradical forms, such as hydrogen peroxide (H 2 O 2 ), hypochlorite, nitric oxide (NO • ), and peroxynitrite. It is important to note that although grouped under the acronym of ROS, different reactive species containing molecular oxygen vary greatly in diffusion coefficient, reactivity, and oxidization potential. Under physiological conditions, trace amounts of signaling ROS, which are tightly regulated by the balance of ROS production and ROS scavengers, form a network that coordinates metabolism with gene transcription and enzymatic activity. 30, 31 Low levels of ROS produced during short periods of ischemia, for example, trigger signaling pathways that confer cardiac protection, a phenomenon coined ischemic preconditioning (IPC), which is mediated, at least in part, through mitochondrial K ATP channels (see below). 32 In addition, low levels of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2-mediated ROS production sensitizes nearby RyRs and triggers Ca 2+ sparks in cardiac myocytess in response to physiological stretch with increased preload 33 and afterload, 34 a process termed X-ROS signaling. Excessive ROS leads to detrimental reactions with cellular lipids and proteins, eliciting maladaptive responses and other abnormalities that compromise cellular and tissue functions, ultimately leading to cell death. [35] [36] [37] The deleterious effects caused by excessive ROS are defined as oxidative stress.
The main sources of ROS in cardiac myocytess include NADPH oxidases, xanthine oxidase, nitric oxide synthase (NOS), and mitochondria. 38, 39 Figure 3 44, 45 As the metabolic hub in cardiac myocytess, mitochondria consume most of the O 2 in cardiac myocytess for energy production, thereby serving as the major source of ROS in the heart.
In the mitochondria, ROS are generated as an inevitable byproduct of OXPHOS, resulting from the premature leak of electrons from the ETC to molecular oxygen. It has been estimated that 0.1% to 1% of the electrons passing through the ETC prematurely leak to O 2 at complexes I, II, or III, •− formation ( Figure 2 ). 46 The ROS production rate in the mitochondria is accelerated by increased proton motive force, by the increased NADH/NAD + ratio, by the increased ratio of reduced coenzyme Q10 to coenzyme Q10, or when the O 2 concentration is raised above physiological levels. 47, 48 Paradoxically, mitochondrial ROS production also increases under condition of low local O 2 concentration. 47, 49 Mitochondrial O 2 •− is converted to H 2 O 2 and O 2 by manganese superoxide dismutase, the primary antioxidant enzyme in mitochondria. 50 H 2 O 2 is then converted to H 2 O and O 2 by cytosolic and mitochondrial scavenging enzymes, glutathione peroxidases, peroxiredoxins, and catalase. The emission of mitochondrial ROS is determined by the tight balance between the redox-dependent ROS production and elimination. The concept of redox-optimized redox balance implies that a reduced mitochondrial redox state (high NADH) not only favors mitochondrial ROS production but also at the same time optimizes ROS elimination through NADPH-dependent ROS scavenging system, such as glutathione and thioredoxin. 51 Cardiac mitochondria are optimized to keep ROS emission at minimum by operating at an intermediate redox state, where ROS emission is highest under oxidized or reduced conditions. 51, 52 During conditions with marked oxidation (such as heart failure), depletion of the antioxidative capacity leads to excessive ROS outflow in spite of reduced O 2
•− production from the ETC, whereas during highly reduced conditions (such as ischemia), excessive O 2
•− production from the ETC overwhelms the antioxidative capacity, in spite of the abundant NADPH levels. [51] [52] [53] The mitochondrial ETC efficiency is impaired under pathological conditions, such as myocardial ischemia 54, 55 and heart failure, 56, 57 resulting in increased electron leak and ROS production. Accumulating ROS levels trigger the opening of mitochondrial channels, including mitochondrial permeability transition pore (PTP) 58 and inner membrane anion channel (IMAC) (Figure 2) , 59 leading to depolarization of the ∆Ψ m and further acceleration of ROS production, a phenomenon termed mitochondrial ROS-induced ROS release. [60] [61] [62] The PTP is a nonselective channel residing on the inner mitochondrial membrane, and it opens with elevated matrix [Ca 2+ ], increased ROS and phosphate levels, and by reduced ) under conditions such as the reduction in l-arginine, the deficiency of cofactor tetrahydrobiopterin (BH 4 ), or increased glutathionylation of eNOS. Superoxide can also interact with preformed NO
• and generate peroxynitrite ONOO − . Figure 4 . Effects of metabolic stresses on cardiac ion channel/transporter function. Schematic illustration of the impact of acute (ischemia/hypoxia) and chronic (heart failure and diabetes mellitus) metabolic stresses on cardiac ion channel/ transporter function and the electrophysiological consequences. Acidosis during acute ischemia leads to opening of sarcK ATP channels, increased activity of Na + /H + exchanger (NHE), and increased late Na + -current (I Na ). ATP depletion during ischemia contributes to the opening of sarcK ATP channels, as well as impairs the function of Na/K ATPase. Other electrophysiological effects from ischemia include the reduction of peak I Na , increased connexin (Cx) conduction, and reduced ryanodine receptor 2 (RyR2) activity. Reduced RyR2 activity during acute ischemia is rapidly reversed on reperfusion, contributing to the spontaneous waves of Ca 2+ release and delayed afterdepolarizations (DADs). A few examples of electrophysiological impact from chronic metabolic stresses associated with heart failure and diabetes mellitus are also illustrated: heart failure reduces peak I Na and multiple Kv (I to , I K ) currents. Diabetes mellitus is also associated with reduction in Kv currents. The increase in sarcK ATP currents lead to action potential duration (APD) shortening, whereas reduced Kv currents and increased late I Na lead to prolonged APD and early afterdepolarizations (EADs). Finally, reduced Na/K ATPase activity, increased RyR2 activity, and increased gap junction conduction during ischemia predispose to arrhythmogenic DADs. adenine nucleotides (ADP or ATP), 63 Brief and reversible PTP opening is considered physiological and serves as a release mechanism to prevent overt mitochondrial cation (especially Ca
2+
) and ROS accumulation. 64 During myocardial ischemia, myocytes experience Ca 2+ overload, high phosphate and low ATP concentrations. These conditions prime PTP for opening when reperfusion triggers ROS generation and mitochondrial Ca 2+ accumulation, leading to prolonged PTP opening and burst ROS release from mitochondria. 63, 64 Pharmacological inhibition of PTP (with cyclosporine A or sanglifehrin A) provides protection against ischemia-reperfusion injury in various experimental models. 65, 66 Recent evidence suggests that dimers of mitochondrial ATP-synthase form the pore-forming component of PTP, 67 and the c subunit of the ATP-synthase complex may be required for PTP-dependent mitochondrial fragmentation and cell death. 68 IMAC, on the contrary, is responsible for anionic currents across the mitochondrial membrane, allowing the passage of O 2
•− generated by ETC from the matrix to the cytoplasmic side of the inner membrane, thereby serving as a mitochondrial O 2
•− efflux and ∆Ψ m depolarization mechanism. 69 During ischemia and reperfusion, mitochondrial O 2
•− production is increased, which leads to increased permeability of IMAC, resulting in a burst in ROS release and ∆Ψ m depolarization. The resulting reversible ∆Ψ m collapse and membrane potential oscillation foster lethal ventricular arrhythmias, which can be abrogated by IMAC inhibitors. 69 During mitochondrial ROS-induced ROS release, depolarized mitochondrial ∆Ψ m depletes NADPH (the level of which is coupled to [NADH] by nicotinamide nucleotide transhydrogenase in mitochondria), thereby leading to rapid dissipation of ROS-eliminating capacity, allowing acceleration of ROS emission from mitochondria. 51, [60] [61] [62] Elevated mitochondrial ROS also impairs ATP production through various mechanisms. Excessive ROS cause oxidative damage to components of the ETC, such as complex I, II, 70 IV, 71 and ATP synthase, 70 impairing ATP generation and further aggravate electron leakage. In addition, O 2
•− activates mitochondrial uncoupling proteins, resulting in increased electron leak and uncoupled O 2 consumption from ATP synthesis. 72, 73 Taken together, excessive cardiac ROS leads to abnormal electric function directly by ROS-mediated signaling and oxidative damage, as well as indirectly by decreasing ATP generation that is required for normal ion channel/transporters functioning. 28, 29 Impaired cardiac metabolism and increased myocardial oxidative stress, depending on the cause and clinical course, can be divided into 2 categories: acute and chronic. Acute cardiac oxidative and metabolic derangements typically occur with myocardial ischemia/reperfusion that results from coronary artery occlusion. Chronic oxidative and metabolic abnormalities, in contrast, occur with conditions such as cardiac hypertrophy, heart failure, and diabetes mellitus. The impact of chronic oxidative and metabolic stresses on cardiac electrophysiology often involves changes in the transcript and protein expression of cardiac ion channels/transporters, which is commonly defined as electric remodeling. 74 Electric remodeling during these chronic cardiac conditions have been extensively reviewed elsewhere. 74, 75 Aside from a few exceptions, therefore, this review will focus on the effects of acute myocardial metabolic and oxidative stress on cardiac electrophysiology.
Mechanisms Linking Impaired Cardiac Metabolism to Ventricular Arrhythmias and SCD
Metabolic Regulation of Cardiac Ca 2+ Handling and Homeostasis
Calcium ions are critical intracellular signaling molecules, responsible for the regulation of numerous cellular processes in cardiac myocytess, including excitation-contraction coupling, gene transcription, enzyme activity, and cell death. 76 The intracellular [Ca 2+ ] concentration fluctuates markedly between systole and diastole, yet the changes in cytosolic [Ca 2+ ] are tightly regulated. Multiple signaling molecules, including calcium/ calmodulin-dependent protein kinase II (CaMKII), PKA, and PKC, are involved in the regulation of these Ca 2+ handling proteins (see review by Bers 76 ). Impaired Ca 2+ homeostasis and handling have been implicated in the mechanical dysfunction and arrhythmogenesis observed in acute myocardial ischemia, 77, 78 as well as in chronic cardiac conditions such as cardiac hypertrophy 79, 80 and heart failure. 81, 82 During myocardial ischemia or metabolic inhibition, various metabolic parameters are markedly altered in cardiac myocytess. For example, ATP levels decrease, cells become progressively acidic with elevated lactate levels, 83 and the levels of phosphate 84 ], at least in part, through decreased extrusion of Ca 2+ or through actual Ca 2+ entry with NCX activity in the reverse mode (Na + out and Ca 2+ in). [92] [93] [94] The activity of SR Ca 2+ uptake (through SERCA) and release (through RyR2) are both inhibited during myocardial ischemia 28 ; however, RyR2 inhibition seems to predominate over reduced SERCA activity during ischemia, reflected in lower frequency of spontaneous Ca 2+ release through RyR2 28, 95 and increased SR Ca 2+ load. 28 On reperfusion or reoxygenation, RyR2 is released from inhibition, producing spontaneous waves of Ca 2+ release, 96 which may contribute to calcium transient/action potential alternans and increase the risk of ventricular arrhythmias ( Figure 4 ; Table 1 ). 97, 98 In addition to the ATP production machinery, mitochondria also harbor Ca 2+ channels and transporters, allowing the transfer of Ca 2+ ions between cytosol and mitochondria, thereby contributing to the dynamic regulation of sarcolemmal Ca 2+ homeostasis. Mitochondria uptake Ca 2+ predominantly through the mitochondrial Ca 2+ uniporter and extrude Ca 2+ mainly through the mitochondrial Na + -Ca 2+ exchanger (Figure 2) . 99 In addition, pharmacological inhibition of mitochondrial uptake through mitochondrial Ca 2+ uniporter with Ru360 has been shown to reduce the incidence of ventricular arrhythmias induced by ischemia-reperfusion in the rodent heart. 105 As the metabolic center in cardiac myocytess, therefore, mitochondria play an important role in transducing changes in cardiac metabolic states to the dynamic regulation of sarcolemmal Ca 2+ , membrane excitability, and electric functioning. Cardiac voltage-gated Na + channels form by the assembly of a pore-forming α subunit and auxiliary β subunits that modulate channel activities. Nav1.5 (SCN5A) is the predominant Nav α subunit expressed in the mammalian myocardium. Currents conducting through Na + channels generate the rapid upstroke (phase 0) of the action potential. In addition, Na + channels, together with cardiac gap junctions, govern the electric conduction velocity in the myocardium. There are 2 effects of Na + channel/transporter dysfunction on arrhythmogenesis: (1) through affecting Na + -Ca 2+ homeostasis, thereby promoting delayed afterdepolarizations and creating reentry substrates and (2) through electrophysiological effects of the channel function. For example, increased late I Na predisposes to action potential duration (APD) prolongation and EADs, both of which are arrhythmogenic and predispose to SCD (Table 1; Figure 4 ).
Metabolic Regulation of
During the metabolic stress that ensues with myocardial ischemia/reperfusion, reduced Na + /K + ATPase (because of reduced ATP and elevated ADP/phosphate levels), increased late I Na (see below for detailed mechanisms), 108 and enhanced NHE (owing to increased cytosolic acidosis) activity 109,110 result in increased cytosolic [Na + ], thereby leading to Ca 2+ overload and increased propensity for ventricular arrhythmias (see above). It has been shown that pharmacological inhibition or knockout of NHE renders cardiac function resistant to ischemia-reperfusion injury.
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In addition to altered Na + /K + ATPase and NHE function, it has been demonstrated that ischemia/metabolic inhibition can trigger Na + influx through connexin hemichannels. 112,113 Under normal conditions, connexin hemichannels located on adjacent intercellular sarcolemmal membranes combine to form gap junctions at the intercalated discs between cardiac myocytess. During ischemia/metabolic inhibition, connexin hemichannels localize to the nonjunctional membrane, turning into nonselective cation channels that are permeable to Na In addition to cytosolic [Na + ], cardiac metabolism also influences electric functioning through modulating sarcolemmal Na + channel activity. 126 During myocardial ischemia, various metabolic derangements result in altered Na + channel properties and function. The ischemic metabolite lysophosphatidylcholine, for example, has been shown to decrease peak Na + current (peak I Na ) and to slow its inactivation. 127 In addition, lysophosphatidylcholine also causes a marked increase in late I Na , thereby increasing myocardial Na + loading. 88 Myocardial acidosis during ischemia is also known to affect the inactivation states of Na + channel, leading to increased late I Na (Table 1; Figure 4) . 89, 90 Cardiac Na + channels are reported to be modulated by AMP-activated PK (AMPK). AMPK is a serine/threonine kinase that is activated by increased cytosolic AMP/ATP ratio to increase ATP production and decrease ATP consumption, thereby functioning as a master metabolic regulator in cardiac myocytes. 128, 129 Mutations in PRKAG2 gene, which encodes the γ2 subunit of AMPK, have been reported to be associated with electric instability and lethal ventricular arrhythmias. [130] [131] [132] For example, PRKAG2 T172D, a constitutively active AMPK mutant, has been shown to slow Na + channels inactivation, leading to increased late I Na , prolonged APD and arrhythmogenic EADs 130 
Metabolic Regulation of K + Channels and Cardiac Repolarization
Various types of voltage-gated K + (Kv) channels and nonvoltage-gated inwardly rectifying channels contribute to myocardial action potential repolarization. 19, 20 Under pathological conditions, such as myocardial ischemia, diabetes mellitus, and heart failure, repolarizing Kv currents in ventricular cardiac myocytess are reduced, leading to delayed repolarization and prolonged APD, which predispose to the development of ventricular arrhythmias and SCD (Figure 4) . 20 Among several types of inwardly rectifying K + channels functioning in mammalian heart, I K1 contributes to the terminal phase of repolarization and the maintenance of resting membrane potentials in ventricular myocytes, 20, 133, 134 whereas currents conducted via sarcolemmal K ATP (sarcK ATP ) channels, gated by intracellular ATP/ADP levels and acidosis, 135 function as immediate sensors of cellular metabolism and play an essential role in electrophysiological responses to metabolic stresses such as myocardial ischemia. 136, 137 Abnormal cardiac repolarization, including QT-interval prolongation and T-wave abnormalities, are often observed in patients with diabetes mellitus, one of the leading chronic metabolic disorders associated with ventricular arrhythmias and SCD. 138, 139 Studies on cellular mechanisms of diabetes mellitus-induced repolarization abnormalities have consistently revealed downregulation of cardiac Kv currents in diabetic heart. 140-142 Multiple mechanisms have been proposed to account for reduced Kv currents during diabetes mellitus. First, post-translational inhibition of Kv channel function occurs in diabetes mellitus. Plasma levels of free fatty acid metabolites, such as palmitoylcarnitine and palmitoyl-CoA, are increased with diabetes mellitus. They have been shown to inhibit cardiac Kv currents directly. 143 Acute treatment with insulin has been demonstrated to reverse diabetes mellitusinduced Kv current reduction, suggesting the primary role of insulin-dependent signaling on Kv channel function. 140 It has been suggested that improved glucose utilization by insulin may be responsible for restored Kv current expression because compounds known to improve glucose utilization (such as dicholoroacetate or l-carnitine) have been shown to normalize cardiac Kv current density with diabetes mellitus. 141 Increased ROS levels also contribute to reduced cardiac Kv currents during diabetes mellitus, and direct incubation with antioxidant glutathione has been shown to restore Kv current expression in myocytes isolated from diabetic hearts. 140 Second, transcriptional regulation of Kv channel expression may reduce Kv currents. Peroxisome proliferator-activated receptor α, a critical regulator of glucose/fatty acid metabolism, is upregulated in diabetic heart and has been suggested to transcriptionally repress cardiac Kv channel expression. 144 Cardiac-specific overexpression of peroxisome proliferatoractivated receptor α downregulates the mRNA and protein expression levels of Kv4.2 and KChIP2, the channel subunits encoding I to , 144 whereas peroxisome proliferator-activated receptor α knockout upregulates I to . 144 Interestingly, it has been recently demonstrated that the activation of phosphoinositide 3-kinase α, a key component of insulin receptor signaling pathway that can be triggered by insulin treatment or exercise training, upregulates mRNA levels of various Kv channels 145, 146 through an Akt-independent mechanism, 147 which may provide the mechanistic explanation for insulinmediated Kv current modulation, as well as the metabolic impact of exercise training on cardiac repolarization. It is important to note that the changes in Kv current observed with diabetes mellitus or exercise training reflect the chronic effects of metabolic stress on Kv channel remodeling, rather than acute channel effects. The sarcK ATP channels are present at high density in the sarcolemmal membrane. SarcK ATP channels are inhibited by ATP and activated by ADP, Mg 2+ , or low pH, conditions that are associated with ischemia, insufficient fuel supply, and increased metabolic stress. 148 On increased metabolic stress with ATP depletion and acidosis (eg, during myocardial ischemia), 149 within seconds in response to acute ischemia, which is likely attributed to the rapid drop in pH (also within seconds of ischemia) in the ischemic tissue. 150 ATP levels, by contrast, deplete at a slower rate and remain in the millimolar range (levels that are sufficient to keep sarcK ATP channels closed) until 10 to 15 minutes after the onset of ischemia. 151 Therefore, ATP depletion may not contribute to sarcK ATP channel opening during the early phase of ischemia.
The cell surface expression density of sarcK ATP channels is high. It has been estimated that the opening of merely 1% of the sarcK ATP channels is sufficient to significantly shorten myocardial APD. 152 The This creates a current sink that slows or blocks electric propagation in the myocardium, predisposing to the development of ventricular arrhythmia (Table 1; Figure 4) . 62, 154 Indeed, pharmacological inhibition of sarcK ATP channels has been shown to reduce the incidence of ventricular arrhythmias in animal models [155] [156] [157] and in humans. [158] [159] [160] Reduced mitochondrial ATP production with impaired respiratory chain function leads to the activation of sarcK ATP channels. During ROS-induced ROS release, for example, dissipation of ∆Ψ m results in cessation of mitochondrial ATP production, leading to sarcK ATP activation, altered myocyte APDs and even ventricular arrhythmias. 59, 62, 161 Interestingly, it has been shown that ATP generated from glycolysis plays a bigger role in modulating sarcK ATP activity than ATP generated from OXPHOS, 162 which is in accordance with recent findings that the key glycolytic enzymes, including glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase, serve as components of the sarcK ATP channel macrocomplex and regulate its function. 163, 164 SarcK ATP channels have also been shown to exhibit reduced sensitivity to ATP-mediated inhibition in diabetic heart, resulting in higher sarcK ATP conductance and greater APD shortening in response to hypoxia. 165 
Non-Ion Channel Mechanisms Linking Metabolism to Ventricular Arrhythmias and SCD
As mentioned above, AMPK functions as a key metabolic sensor and regulator in cardiac myocytess. It has been reported that specific mutations in PRKAG2, the γ2 regulatory subunit of AMPK, lead to a glycogen storage cardiomyopathy characterized by ventricular pre-excitation and cardiac hypertrophy. 166, 167 The structural abnormalities associated with PRKAG2 mutations, including the glycogen accumulation and ventricular hypertrophy, result in abnormal conduction that predisposes to ventricular arrhythmias. 166, 167 In addition to AMPK, patients with inherited fatty acid oxidation disorders exhibit high incidence of ventricular arrhythmias, conduction defects and SCD, 168 which can be attributed to the accumulation of arrhythmogenic intermediary metabolites of fatty acids. 168 Fatty acid metabolites, such as lysophosphatidylcholine, accumulate during myocardial ischemia, contributing to the formation of arrhythmogenic substrates. 88 Consistent with these findings, a transgenic mouse model of cardiac-specific overexpression of fatty acid transport protein 1 (α-MHC FATP1) has been shown to exhibit increased myocardial uptake and accumulation of free fatty acids, leading to arrhythmogenic electric changes including QT prolongation. 169 Taken together, these data suggest that abnormal cardiac metabolism can lead to ventricular arrhythmias and SCD through non-ion channel mechanisms.
Mechanisms Linking Increased Cardiac Oxidative Stress to Ventricular
Arrhythmias and SCD
Myocardial Oxidative Stress and Cardiac Na + Channels
Abnormal cardiac Na + channel function is often observed in cardiac diseases, such as myocardial ischemia 170, 171 and heart failure, 91, 172 conditions that are associated with increased cardiac oxidative stress. Na + channel abnormalities can be categorized as loss-or gain-of function. Loss-of-function Na + channel abnormality leads to reduced peak I Na , resulting in conduction block that potentiates re-entrant type ventricular arrhythmias. 173 Gain-of-function Na + channel abnormality, in contrast, results in the increase in late I Na , which can lead to prolongation of APDs, EADs, reverse mode NCX transport, and subsequent Ca 2+ overload in sarcomere, all of which predispose to ventricular arrhythmias. 122, 174 ROS have been demonstrated to affect Na + channel function through multiple mechanisms. Transcriptionally, ROS have been shown to reduce Nav1.5 channel expression by reducing mRNA expression. 175, 176 At the protein level, ROS have been shown to impair Nav1.5 channel inactivation through direct oxidation at the methionine residues of Nav1.5 channel protein. 177 Elevated mitochondrial ROS are known to reduce peak I Na by modifying Nav1.5 conductance through post-translational mechanisms without affecting cell surface expression of Nav1.5. 57 The slowly inactivating component of Na + current (late I Na ), on the contrary, is known to be augmented by ROS in cardiac myocytess. 121, 122, 174 For example, increased H 2 O 2 has been shown to increase the open probabilities of Na + channel, leading to increased late I Na , 121, 122 and arrhythmogenic changes including prolongation of APDs, EADs, and cytosolic Ca 2+ overload ( Figure 5 ; Table 2 ). 122, 174 In addition to direct ROS-dependent effects on Na + channels, ROS also modulate Na + channel activities indirectly by altering membrane lipid environment June 5, 2015 altering membrane Na + channel protein expression levels. 57 The reduced peak I Na can be restored by mitochondrial antioxidants NAD + or Mito-TEMPO [(2,2,6,6-Tetramethylpiperidin-1-yl) oxyl] treatment. 57 Consistent with these findings, NAD + treatment has been shown to improve myocardial conduction abnormality that is associated with reduced peak I Na in human failing heart. 57 The link between mitochondrial ROS and I Na regulation is also observed in the hereditary arrhythmia syndromes. One of the Brugada syndrome-causing mutations, A280V mutation in glycerol-3-phosphate dehydrogenase 1-like protein, has been demonstrated to reduce peak I Na by increasing cytosolic NADH levels and mitochondrial ROS. 123, 179 Peak I Na reduction by A280V glycerol-3-phosphate dehydrogenase 1-like is abrogated by the treatment of NAD + or Mito-TEMPO. 123 Taken together, these data suggest the important role of mitochondrial ROS in transducing the altered cardiac metabolic states (NADH/NAD + levels) to the regulation of cardiac Na + channels and membrane excitability.
During acute ischemia, myocardial NO
• production is enhanced owing to increased NOS (especially eNOS) activity 180 and conversion of tissue nitrate to NO
• . 181 Increased NO
• production and elevated NOS activities play a critical role in the cardioprotective effects of IPC (see Myocardial ROS and Potassium Channels Section of this article), which has been extensively reviewed previously. 182, 183 Elevated NO • has been shown to increase late I Na , 184 which can be abolished by reducing agents glutathione and DTT, 184, 185 suggesting that NO
• modulates Na + channel activities by oxidizing Na + channel or its regulatory proteins. Interestingly, others report that NO
• decreases peak I Na through reducing the open probability and the surface expression of functional Na + channels, which are mediated indirectly through a PKG/PKA-dependent pathway. -handling and regulatory proteins harbor methionines or thiol groups that are susceptible to the direct modification by ROS or reducing agents, thereby sensitive to the altered redox states during cardiac diseases.
In general, elevated ROS levels in cardiac myocytess are known to result in a net increase in intracellular [Ca 2+ ]. 188 The direct application of H 2 O 2 or increased mitochondrial ROS has been shown to increase I CaL and its sensitivity to isoproterenol stimulation in ventricular myocytes. 189 In addition, oxidized low-density lipoprotein has been demonstrated to stimulate I CaL through lysophosphatidylcholine-induced mitochondrial ROS. 190 Nevertheless, there are conflicting reports showing reduced cardiac I CaL in the presence of elevated oxidative stress. 191, 192 The discrepant findings in the effects of ROS on cardiac I CaL may be explained by the differences in the experimental design, animal species, and type of ROS involved.
The results on the impact of increased oxidative stress on other Ca 2+ -handling proteins, in contrast, are more consistent. Excessive ROS increases the open probability of RyR2, enhancing the release of Ca 2+ from SR. 193 Calcium sparks from RyR2 are increased in response to photoactivated or chemicalinduced mitochondrial ROS. 194 In contrast to RyR2, SERCA activity is reduced on increased cardiac ROS, [195] [196] [197] which can be, at least in part, attributed to reduced ATP supply for SERCA pump owing to mitochondrial dysfunction. 38 Cardiac NCX, which normally extrudes Ca 2+ from cytosol in exchange for Na + , has been shown to be activated in the reverse mode by increased oxidative stress, thereby increasing cytosolic [Ca 2+ ] (Table 2; Figure 5 ). 198, 199 CaMKII is activated by ROS, and it is known to play a critical role in regulating calcium-handling proteins in response to increased cardiac oxidative stress. 200 For example, activated CaMKII augments I CaL by phosphorylating Cav1.2 channel subunit and increasing its open probability. 201 Phosphorylation of RyR2 by CaMKII increases SR Ca 2+ leak, promoting cytosolic Ca 2+ overload and delayed afterdepolarizations. 200 Taken together, the net impact of increased oxidative stress , and I K1 ) and leads to reduced gap junction protein connexin (Cx) 43 and reduced sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) activity. Increased ROS inhibit normal operation of Na + /Ca 2+ exchanger (NCX; Na + in, Ca 2+ out) and promote the reverse mode of NCX activity (Na + out, Ca 2+ in). The increase in sarcK ATP currents lead to action potential duration (APD) shortening, whereas reduced Kv currents and increased late I Na lead to prolonged APD and early afterdepolarizations (EADs). Increased RyR2 activity, reduced SERCA function, and reverse mode NCX activity lead to cytosolic Ca 2+ overload and predispose to delayed afterdepolarizations (DADs). -handling proteins leads to cytosolic Ca 2+ overload and depletion of SR Ca 2+ store, resulting in detrimental changes, such as arrhythmogenic delayed afterdepolarizations and contractile dysfunction.
As discussed earlier in this review, mitochondria also play an important role in the regulation of Ca 2+ in cardiac myocytess. Increased oxidative stress is known to modulate mitochondrial [Ca 2+ ] by altering mitochondrial ion channel activities, contributing to the perturbation of cytosolic Ca 2+ homeostasis. For example, increased ROS during myocardial ischemia depolarize ∆Ψ m , 202 forcing mitochondrial NCX into reverse mode and drives Ca 2+ from cytosol into mitochondria.
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Physiologically, mitochondrial Ca 2+ is required for normal ETC function and serves as a positive effector of OXPHOS. Ca 2+ overload, however, leads to increased mitochondrial ROS production through mechanisms including increased electron leakage, 204, 205 enhanced NO • production, which is known to inhibit complex IV and augment ROS production from complex III, 206 and reduced cytochrome c-mediated respiration. 207, 208 In addition, pathological mitochondrial Ca 2+ overload has been shown to increase NO
• and ROS production in cardiac myocytess. 209 These data suggest a positive feedback loop between ROS-induced Ca ] increase, leading to increased ROS production. ROS overproduction induced by elevated mitochondrial [Ca 2+ ] results in further increase in mitochondrial Ca 2+ and ROS levels. The Ca 2+ load and ROS produced from this positive feed-forward loop can overwhelm the cellular capacity of ROS scavenging and Ca 2+ clearance, resulting in cellular damage and electric instability that predispose to ventricular arrhythmias and SCD. 210 It is worth noting that during heart failure, mitochondrial Ca 2+ uptake/accumulation is actually reduced (because accumulated cytosolic Na + during heart failure inhibits mitochondrial Ca 2+ uptake via activation of mitochondrial Na + -Ca 2+ exchanger), 119,120 which also favors ROS production (by impairing mitochondrial energetics and oxidizing NAD(P)H). 213 of Ca 2+ channel subunits, which may contribute to the cardioprotective effects of IPC by limiting Ca 2+ influx during ischemia. 212 The effects of NO • on RyR2 is concentration dependent. Physiological NO
• levels (≈1 μmol/L) do not affect RyR2 activity, whereas supraphysiological levels (≥100 μmol/L) inhibit RyR2 activity. 214 Peroxynitrite, on the contrary, activates RyR2 by oxidizing its cysteine residues. 214 SERCA2a, by contrast, is inhibited by peroxynitrite-mediated tyrosine nitration. PKA pretreatment can prevent the inhibitory effects of peroxynitrite on SERCA2a by inducing dissociation of phospholamban from SERCA2a. 215 
Myocardial ROS and Potassium Channels
Increased oxidative stress is known to inhibit repolarizing Kv currents including I to and several delayed rectifier I K (I Kr , I Ks , and I Kur ) in mammalian ventricular myocytes. [216] [217] [218] These effects are reversible by raising cellular antioxidant glutathione levels.
140,219 ROS have been shown to regulate Kv current expression by reducing the transcript/protein expression of the Kv channel subunits 218 and by modulating the phosphorylation of these channel subunits through PKs such as PKA, PKC, or protein tyrosine phosphatases. [220] [221] [222] Cardiac Kv channels are also regulated by NO
• . It has been reported that NO
• inhibits human cardiac Kv4.3 channel, thereby reducing the transient outward K + current I to . 223 NO • also blocks Kv1.5 channel through S-nitrosylation and the activation of cGMP/ PKG pathway. 224 Myocardial ROS also regulates myocyte membrane excitability through sarcK ATP channels. During myocardial ischemia, fuel substrate deprivation and increased oxidative stress depolarize the mitochondrial network, leading to fluctuated ∆Ψ m and ATP production levels, which result in oscillation of sarcK ATP currents and APDs. 69, 225 The ∆Ψ m depolarization of the mitochondrial network is potentiated by widespread ROS production induced by focal increases in mitochondrial ROS (ROS-induced ROS release). 60, 62, 226 IMAC plays a critical role in ∆Ψ m depolarization on increased ROS; pharmacological inhibition of IMAC has been shown to prevent ∆Ψ m depolarization and the oscillation of sarcK ATP currents and APD, 59 as well as preventing ventricular arrhythmias in mammalian hearts 227, 228 during myocardial ischemia. Another group of K ATP channels, residing on the mitochondrial inner membrane (mito-K ATP channels), contribute importantly to the protective effects of IPC, an endogenous cellular protective mechanism involving brief periods of ischemia that confers protection against infarction produced by a subsequent prolonged ischemia. 148, 229 Under physiological conditions, mito-K ATP channel opening enhances mitochondrial ROS production, triggering downstream signaling pathways involved in gene transcription and cell growth. 230 During IPC, the activation of mito-K ATP channels allows mitochondrial K + influx, resulting in partially depolarized ∆Ψ m , which leads to a compensatory increase in proton pumping and cellular respiration to maintain ∆Ψ m and ETC activity. 229 Partially dissipated ∆Ψ m induced by mito-K ATP channel opening blunts mitochondrial Ca 2+ accumulation during ischemia and reduces PTP opening on reperfusion, 231,232 both of which contribute to the protection against cell death by IPC. The opening of mito-K ATP channel also triggers the production of protective ROS, which activates a PKC-dependent pathway that confers cardiac protection by reducing deleterious postischemic ROS production. 233, 234 Interestingly, NO • , a physiologically important free radical, has been shown to potentiate mito-K ATP opening 235 and triggers both early and delayed IPC. 236, 237 In addition, mito-K ATP opening during ischemia provides additional K + influx to maintain mitochondrial volume, which is critical to maintain the normal function of mitochondria and ETC. 230 Pharmacological inhibition of mito-K ATP channels abrogates the antiarrhythmic effects of IPC, 238 and several mito-K ATP channel openers are shown to provide protective effects against ischemia-induced cardiac arrhythmias. 157, 239, 240 
Mitochondrial ROS and Cardiac Gap Junction Regulation
Cardiac gap junctions are formed by the assembly of a pair of juxtaposed intercellular hemichannels with each hemichannel consisting of 6 connexin (connexin) proteins. Gap junctions mediate the intercellular communication of small metabolites and ions and play an essential role in cardiac electric conduction. 241 Among the 3 principal connexin isoforms (connexin 40, connexin 43, and connexin 45) expressed in the heart, connexin 43 is the predominant isoform expressed in ventricular myocytes. 242 Ventricular connexin 43 expression has been shown to be downregulated with myocardial ischemia, 243, 244 and heart failure, 245, 246 which can lead to slowed conduction, increased electric heterogeneity and abnormal anisotropic properties of the ventricles. 247, 248 These changes can facilitate the initiation and maintenance of ventricular arrhythmias and SCDs. 249, 250 Cardiac renin-angiotensin system (RAS) activity is increased on acute ischemia, contributing to the acute and chronic myocardial remodeling in response to ischemia. 251, 252 RAS activation is known to increase myocardial oxidative stress and downregulate ventricular gap junction protein connexin 43. [253] [254] [255] Transgenic mouse models with enhanced cardiac RAS activity 255, 256 have high incidence of conduction abnormality, ventricular arrhythmias and sudden death owing to reduced cardiac connexin 43 and abnormal gap junction function. 255, 256 Using a transgenic mouse model of cardiac-restricted angiotensin-converting enzyme overexpression (ACE8/8), 255 we have demonstrated that increased cardiac RAS activity leads to increased activity of cSrc, a redox-sensitive tyrosine kinase, by increasing cSrc phosphorylation at Tyr 416 , in the ventricular myocardium. The activation of cSrc leads to connexin 43 downregulation, impaired gap junction function, slowed cardiac conduction, and increased incidence of ventricular arrhythmias and SCD. 35, 257 The downregulation of connexin 43 and increased risk for arrhythmias in angiotensin-converting enzyme 8/8 mice are alleviated by pharmacological inhibition of RAS 258 and cSrc. 257 It has been shown that increased myocardial p-cSrc leads to connexin 43 reduction through the competition between p-cSrc and connexin 43 for the binding with zonula occludens-1, a scaffolding protein at the intercalated disk, resulting in connexin 43 destabilization and degradation. 259 Elevated p-cSrc levels also impair gap junction function by phosphorylating connexin 43 at tyrosine residues. 260 Using the same ACE 8/8 mouse model, we have also shown that cardiac mitochondrial ROS were markedly increased with enhanced RAS activity. 35, 257 Treatment with mitochondria-targeted antioxidant Mito-TEMPO, but not with other types of antioxidants, decreases cSrc phosphorylation, preserves connexin 43 expression, improves gap junction function, and abolishes ventricular arrhythmias and SCD in ACE 8/8 mice. 35 Although the clinical evidence suggests that exogenous antioxidants do not prevent SCD, 261 these data support a role for ROS, and suppression of endogenous, mitochondria-specific ROS may be an effective therapeutic approach.
Mechanistically, we have recently demonstrated that enhanced RAS signaling increases S-nitrosylation of cardiac caveolin-1 (Cav1), an intrinsic inhibitor of cSrc, resulting in Cav1-cSrc dissociation and subsequent cSrc activation. Cav1 S-nitrosylation upon enhanced RAS signaling is mediated by increased Cav1-eNOS binding that is dependent on elevated mitochondrial ROS. 262 Consistent with these findings, Cav1 knockout mice exhibit increased cSrc activation, reduced connexin 43 expression, myocardial conduction defect, and increased inducibility of ventricular arrhythmias. 262 Taken together, these data suggest the critical roles of mitochondrial oxidative stress and Cav1 in AngII-induced gap junction remodeling and arrhythmia. As mitochondrial ROS are increased in myocardial ischemia 251, 252 and heart failure, 56, 57 both of which are associated with RAS activation, reduced ventricular connexin 43 and increased risk for ventricular arrhythmias and SCD, it would be of great interest to test whether the treatment with mitochondria-targeted antioxidant 
Effects of Chronic Versus Acute Metabolic Derangement and Oxidative Stress on Arrhythmogenicity
In this review, we have primarily focused on the impact of acute myocardial metabolic and oxidative stress on cardiac electrophysiology, arrhythmogenicity, and SCDs. It is important to note that chronic conditions associated with metabolic derangements and excessive oxidative stress such as aging, 263 hypoxia/obstructive sleep apnea, 264 chronic kidney disease, 265 and diabetes mellitus, 138,139 also result in arrhythmogenic changes that predispose to SCDs. Many of the arrhythmogenic changes related to these chronic conditions involve electric remodeling 74, 75 and the creation of arrhythmogenic substrates such as fibrosis, 266, 267 which may not be seen with acute metabolic and oxidative stress. Nevertheless, the effects of acute and chronic metabolic/oxidative stress on cardiac electric function may not be mutually exclusive. The acute application of mitochondria-targeted antioxidant, for example, can restore the reduced peak I Na observed with chronic heart failure. 57 In addition, reduced Kv currents in diabetic heart can be reversed by acute insulin treatment. 140 These observations suggest the contribution of the acute, modifiable metabolic/ oxidative stress in these chronic conditions, which can be rapidly reversed by targeting the underlying metabolic/oxidative derangement. It is difficult to distinguish whether acute metabolic/oxidative changes exacerbate and amplify chronic changes or whether acute changes are unrelated to the chronic changes and simply occur on an arrhythmogenic background. Additional studies are required to address these possibilities.
Conclusions
In summary, metabolic derangement and increased oxidative stress are prevalent in arrhythmogenic cardiac conditions, particularly during myocardial ischemia. Impaired cardiac metabolism and increased ROS production can lead to malfunction of various cellular mechanisms that are required to maintain normal electric functioning and intracellular ionic homeostasis in cardiac myocytess. The impact of altered cardiac metabolism and increased oxidative stress on cardiac arrhythmogenicity is summarized in Table 1 , Figure 4 and Table 2, Figure 5 , respectively. Because the conventional antiarrhythmic drugs targeting ion channels are often proarrhythmic, understanding the mechanisms linking abnormal metabolism and oxidative stress to cardiac arrhythmias may help to develop novel therapeutics to reduce the risk of life-threatening arrhythmias and SCD in patients with cardiac diseases. These observations suggest that therapeutics tailored to ameliorate metabolic derangement and oxidative stress may prove a more efficacious alternative to traditional ion channel blocking drugs to address arrhythmia in associated with cardiac diseases, and a list of potential novel therapeutics are summarized in Table 3 . 
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